Published in Dig Dis Sci on August 21, 2008
Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IκBα. PLoS One (2012) 1.06
Risk association between the NF-κB1 -94ins/delATTG promoter polymorphism and inflammatory bowel diseases: a meta-analysis. Dig Dis Sci (2012) 0.81
Co-stimulatory CD28 and transcription factor NFKB1 gene variants affect idiopathic recurrent miscarriages. J Hum Genet (2016) 0.75
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (2006) 27.49
A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet (2006) 15.14
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl (1989) 9.56
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis (2000) 6.90
Activation of nuclear factor kappa B inflammatory bowel disease. Gut (1998) 4.14
Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology (1998) 3.82
Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet (1980) 3.71
Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci U S A (1998) 2.88
A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet (1999) 2.88
Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol (2006) 2.61
Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet (2003) 2.33
Chronic inflammation and susceptibility to bacterial infections in mice lacking the polypeptide (p)105 precursor (NF-kappaB1) but expressing p50. J Exp Med (1998) 1.79
Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol (2003) 1.65
High-density genome scan in Crohn disease shows confirmed linkage to chromosome 14q11-12. Am J Hum Genet (2000) 1.52
High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology (2000) 1.47
Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest (2006) 1.45
A major quantitative trait locus on chromosome 3 controls colitis severity in IL-10-deficient mice. Proc Natl Acad Sci U S A (2001) 1.30
Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World J Gastroenterol (2004) 1.25
NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology (2002) 1.20
Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World J Gastroenterol (2005) 1.19
Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis. Gut (2004) 1.17
Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol (1995) 1.15
Association of NFKBIA polymorphism with colorectal cancer risk and prognosis in Swedish and Chinese populations. Scand J Gastroenterol (2007) 1.15
Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology (2000) 1.13
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther (2005) 1.05
A polymorphism of the NFKBIA gene is associated with Crohn's disease patients lacking a predisposing allele of the CARD15 gene. Int J Colorectal Dis (2003) 1.05
A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int J Immunogenet (2005) 0.98
Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol (2007) 0.96
Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm Bowel Dis (2007) 0.95
A major quantitative trait locus on mouse chromosome 3 is involved in disease susceptibility in different colitis models. Gastroenterology (2005) 0.92
Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease. Gut (1999) 0.90
A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population. Inflamm Bowel Dis (2005) 0.84
No association of the NFKB1 promoter polymorphism with ulcerative colitis in a British case control cohort. Gut (2005) 0.84
ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases. Scand J Gastroenterol (2007) 0.83
Role of the NFKB1 -94ins/delATTG promoter polymorphism in IBD and potential interactions with polymorphisms in the CARD15/NOD2, IKBL, and IL-1RN genes. Inflamm Bowel Dis (2006) 0.83
DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn's disease. Inflamm Bowel Dis (2006) 0.80
Polymorphisms in NFKBIA and ICAM-1 genes in New Zealand Caucasian Crohn's disease patients. J Gastroenterol Hepatol (2007) 0.78
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 3.32
Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol (2004) 3.07
Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci (2010) 2.86
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res (2009) 2.49
Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol (2006) 2.21
Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis (2013) 2.18
Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2012) 2.10
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98
Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol (2012) 1.89
A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol (2013) 1.89
Geographical variability and environmental risk factors in inflammatory bowel disease. Gut (2013) 1.84
Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol (2008) 1.79
Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin Gastroenterol Hepatol (2009) 1.78
Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol (2009) 1.77
Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. Leuk Res (2008) 1.66
Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol (2003) 1.65
Lower prevalence of Helicobacter pylori infection in patients with inflammatory bowel disease but not with chronic obstructive pulmonary disease - antibiotic use in the history does not play a significant role. Helicobacter (2004) 1.59
Novel mutations of the ATP7B gene among 109 Hungarian patients with Wilson's disease. Eur J Gastroenterol Hepatol (2007) 1.57
Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology (2010) 1.50
Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat (2009) 1.46
[Autoimmune pancreatitis]. Orv Hetil (2008) 1.43
Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis (2007) 1.42
[Appearing of bone marrow derived stem cells in healthy and regenerating colonic epithelium]. Orv Hetil (2009) 1.40
[Treatment prospects of lysosomal storage disorders]. Orv Hetil (2008) 1.40
Does dermatitis herpetiformis result in bone loss as coeliac disease does? A cross sectional study. Rev Esp Enferm Dig (2013) 1.40
Persistent long-term human herpesvirus 6 (HHV-6) infection in a patient with langerhans cell histiocytosis. Pathol Oncol Res (2007) 1.37
Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS One (2012) 1.35
Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll" ? World J Gastroenterol (2006) 1.35
Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis (2009) 1.35
Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol (2007) 1.32
Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis (2006) 1.31
The R1141X loss-of-function mutation of the ABCC6 gene is a strong genetic risk factor for coronary artery disease. Genet Test Mol Biomarkers (2010) 1.31
Mucocele of the appendix: an unusual cause of lower abdominal pain in a patient with ulcerative colitis. A case report and review of literature. World J Gastroenterol (2005) 1.28
New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol (2007) 1.27
Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat (2009) 1.25
Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World J Gastroenterol (2004) 1.25
Inflammation, adenoma and cancer: objective classification of colon biopsy specimens with gene expression signature. Dis Markers (2008) 1.24
Mutation history of the roma/gypsies. Am J Hum Genet (2004) 1.24
Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol (2012) 1.23
Association of beta-defensin 1 single nucleotide polymorphisms with Crohn's disease. Scand J Gastroenterol (2008) 1.22
New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. J Med Genet (2013) 1.22
Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res (2006) 1.20
IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohns Colitis (2010) 1.20
Highly expressed genes are associated with inverse antisense transcription in mouse. J Genet (2007) 1.19
Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World J Gastroenterol (2005) 1.19
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer (2008) 1.16
Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results. Cancer Epidemiol Biomarkers Prev (2008) 1.15
Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol (2007) 1.15
HAEdb: a novel interactive, locus-specific mutation database for the C1 inhibitor gene. Hum Mutat (2005) 1.14
Antioxidant measurements. Physiol Meas (2007) 1.14
Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis (2011) 1.09
Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. BMC Med Genomics (2010) 1.09
Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One (2010) 1.08
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis (2012) 1.08
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther (2011) 1.06
Three-dimensional virtual microscopy of colorectal biopsies. Arch Pathol Lab Med (2005) 1.06
Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel Dis (2007) 1.05
Herpes in STAT1 gain-of-function mutation [corrected]. Lancet (2012) 1.04
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res (2008) 1.02
Wireless capsule endoscopy in the diagnosis of helminthiasis. Gastrointest Endosc (2007) 1.02
Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis (2009) 1.02
Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. Inflamm Bowel Dis (2010) 1.02
High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol (2003) 1.02
Dysplasia-carcinoma transition specific transcripts in colonic biopsy samples. PLoS One (2012) 1.01
Genetic polymorphisms of NOD1 and IL-8, but not polymorphisms of TLR4 genes, are associated with Helicobacter pylori-induced duodenal ulcer and gastritis. Helicobacter (2007) 1.01
Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis (2011) 0.99
Serrated pathway: alternative route to colorectal cancer. World J Gastroenterol (2013) 0.99